Daxor (NASDAQ:DXR) versus Embecta (NASDAQ:EMBC) Head-To-Head Comparison

Embecta (NASDAQ:EMBC) and Daxor (NASDAQ:DXR) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, risk, dividends, analyst recommendations, institutional ownership, profitability and earnings.

Institutional & Insider Ownership

93.8% of Embecta shares are held by institutional investors. Comparatively, 1.3% of Daxor shares are held by institutional investors. 0.4% of Embecta shares are held by company insiders. Comparatively, 59.0% of Daxor shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Profitability

This table compares Embecta and Daxor’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Embecta	6.97%	-18.54%	11.43%
Daxor	N/A	N/A	N/A

Earnings & Valuation

This table compares Embecta and Daxor”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Embecta	$1.12 billion	1.07	$78.30 million	$1.35	15.33
Daxor	$2.61 million	14.39	N/A	N/A	N/A

Embecta has higher revenue and earnings than Daxor.

Dividends

Embecta pays an annual dividend of $0.60 per share and has a dividend yield of 2.9%. Daxor pays an annual dividend of $0.03 per share and has a dividend yield of 0.4%. Embecta pays out 44.4% of its earnings in the form of a dividend.

Volatility and Risk

Embecta has a beta of 1.25, suggesting that its stock price is 25% more volatile than the S&P 500. Comparatively, Daxor has a beta of -0.51, suggesting that its stock price is 151% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent recommendations and price targets for Embecta and Daxor, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Embecta	0	1	1	0	2.50
Daxor	0	0	1	0	3.00

Embecta presently has a consensus price target of $23.00, indicating a potential upside of 11.11%. Daxor has a consensus price target of $24.75, indicating a potential upside of 219.35%. Given Daxor’s stronger consensus rating and higher possible upside, analysts plainly believe Daxor is more favorable than Embecta.

About Embecta

Embecta Corp., a medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes. Its products include pen needles, syringes, and safety injection devices, as well as digital applications to assist people with managing patient's diabetes. The company primarily sells its products to wholesalers and distributors in the United States and internationally. Embecta Corp. was founded in 1924 and is headquartered in Parsippany, New Jersey.

About Daxor

Daxor Corporation, a medical device company, provides blood volume measurement technology focused on blood volume testing. The company develops and markets BVA-100 Blood Volume Analyzer, a diagnostic blood test to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms for used in a broad range of medical and surgical conditions. The company was formerly known as Idant Corporation and changed its name to Daxor Corporation in May 1973. Daxor Corporation was incorporated in 1971 and is headquartered in Oak Ridge, Tennessee. Daxor Corporation is a subsidiary of Estate Of Joseph Feldschuh.